top of page

Wedbush analyst David Nierengarten joins BiotechTV for Analyst Thursdays from San Francisco

David Nierengarten gives his take on biotech and discusses Blueprint Medicines, G1 Therapeutics, Y-mAbs, Fusion Pharma, Sutro Biopharma, Scholar Rock, and more.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page